trial shows car t-cell therapy prolongs remission in paediatric relapsed or refractory all
Published 9 years ago • 67 plays • Length 6:42Download video MP4
Download video MP3
Similar videos
-
5:01
challenges of car t-cell treatment in pediatric all
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
3:05
treating pediatric all with chimeric antigen receptor (car) t-cell therapy
-
2:27
the potential of car t-cell therapy in combination with antibodies for the treatment of all
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
8:27
anti cd7 car t-cell therapy in t-all
-
1:21
the future of treating pediatric all with car-t
-
1:39
the role of myeloid cells in car-t cell therapy
-
1:05
the car t-cell therapy race
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:10
car t-cell therapy video
-
2:05
the cost-effectiveness of car t-cell therapy
-
4:44
accessing myeloma car t-cell therapy clinical trials
-
1:58
car t-cell therapy and all: the current landscape
-
2:31
remote management of patients undergoing car t-cell therapy
-
6:59
responses to car t-cell therapy still strong after one year in patients with refractory nhl
-
8:27
phase i trial of donor-derived cd7 car t-cells for t-all
-
4:24
key questions in the field of cd19 car t-cell therapy